New Product Planning

pharmaceutical new product planning

Our blend of clinical development experience, marketing toolbox and therapeutic expertise uniquely positions our team to support the pharmaceutical new product planning and development process. We have a long history of assisting clients in developing and implementing strategies that ensure differentiation and maintained product access for patients. Our success is driven by a deep understanding of the nuances of relevant markets and products which informs realistic, targeted and data-driven recommendations.

Herspiegel Consulting delivers strategic assessments and insightful processes in new product planning thus creating a structure for decision making. We help advance the development process with actionable insights to evaluate market potential, prioritize launch markets and develop competitive lifecycle management plans.

Recent Projects Include:

  • • Market landscape assessment and opportunity sizing

  • • Global disease strategy at corporate, BU and asset level strategy

  • • Early assets management including stage gate decision support

  • • Launch prioritization

  • • Creation of a dynamic forecast model

  • • Investor deck development

  • • Lifecycle management plan

Latest Blogs

Planning for 505(b)2 Commercial Success

October 17, 2018
Unlike generics and biosimilars, 505(b)2 regulatory products likely involve a unique claim. While 505(b)...
Read more

Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices

February 12, 2018
The impact of drug shortages is not new within the healthcare system, particularly at the hospital level...
Read more

FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers

January 24, 2018
Citizen petitions have historically been a tool in the brand manufacturer’s toolkit of “product life...
Read more

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

April 14, 2017
  The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic ...
Read more